Optimizing dosing and fixed-dose combinations of rifampicin, isoniazid, and pyrazinamide in pediatric patients with tuberculosis: a prospective population pharmacokinetic study.
Paolo DentiRoeland E WasmannAnnelies van RieJana WincklerAdrie BekkerHelena RabieAnneke C HesselingLouvina E van der LaanCarmen Gonzalez-MartinezHeather J ZarGerry DaviesLubbe WiesnerElin M SvenssonHelen M McIlleronPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
Current pediatric FDC doses resulted in low rifampicin exposures. Optimal dosing of all drugs cannot be achieved with the current FDCs. We propose a new FDC formulation and revised weight-bands.